Expert Corporate Governance Service (ECGS)
EUR 1000.00 For Business Accounts Only

Evotec – AGM 16 june 2020

General: The AGM is to be held in the form of a virtual AGM in accordance with the German Law to Mitigate the Consequences of the COVID-19 Pandemic. The physical presence of shareholders or their authorised proxies is not possible. The voting rights may therefore be exercised solely by postal vote or by granting authority to the proxies designated by the Company.


One of the major shareholders, Roland Oetker, is the former President and since 2008 the Honorary President of DSW, the local partner of ECGS. This report has been prepared using standard ECGS guidelines.


Evotec was founded 1993 in Hamburg. Today, the Company is a publicly listed drug discovery and development company that operates globally, largely through external alliances with pharmaceutical and biotechnology companies, academic institutions, patient advocacy groups and venture capitalists.


The Company has issued 151,267,190 shares that amount to a share capital of EUR 151,267,190. As of 30 April 2020, Morgan Stanley Investment Management Inc. and Novo Holdings A/S each held between 10% and 15% and ROI Verwaltungsgesellschaft mbH/Roland Oetker, T.Rowe Price Group Inc., Allianz Global Investors and DWS Investment GmbH each held between 5% and 10% of the Company's shares.


In financial year 2019, Group revenues increased by 18.9% to EUR 446.4m, operating income decreased by 19.2% to EUR 62.6m and net income attributable to the shareholders of Evotec SE decreased by 54.8% to EUR 38.1m.


Item 6: We recommend to oppose the Restricted Share Plan 2020 as we do not consider its performance targets as challenging enough.


Evotec is a holding company engaged as a drug discovery solutions company providing drug discovery capabilities to pharmaceutical and biotechnology companies as well as to academic institutions. These drug discovery solutions are provided in form of fee-for service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Co. is primarily involved in the areas of neuroscience, pain, metabolic diseases, oncology and inflammation. Co. provides its drug discovery activities under the banners of EVT Execute, EVT Integrate and EVT Innovate. Co.'s operations are divided into two segments: EVT Execute and EVT Innovate.


Founded in 1995, Proxinvest is an independent proxy firm supporting the engagement and proxy analysis processes of investors. Proxinvest mission is to analyse corporate governance practices and resolutions proposed at general meetings of listed firms.

Proxinvest main services are :

  • ​Proxy reports
  • Definition and monitoring of client customized voting guidelines
  • Corporate Governance Data and Rating
  • Thematic research
  • Engagement support

Proxinvest has been a pioneer and champion of good corporate governance and has grown into a recognised expert in the field.

Proxinvest is independently-owned and only works for investors : Proxinvest does not provide consulting services to the companies it covers, mitigating related risks to its clients and ensuring the independence of our analysis. As a result Proxinvest is able to take a robust, independent, engaged and unconflicted view of the companies in which our clients invest.

As Managing Partner of Expert Corprate Governance Service Ltd (ECGS), Proxinvest has built a large network of corporate governance experts to support clients in corporate governance analysis worldwide. 

Expert Corporate Governance Service (ECGS)

Other Reports on these Companies
Other Reports from Proxinvest
Other Reports from these Analysts

ResearchPool Subscriptions

Get the most out of your insights

Get in touch